Bleeding risk and safety profile related to the use of eptifibatide: a current review

被引：10

作者：

Saab, Fadi ^{[1
]}

Ionescu, Costin ^{[1
]}

Schweiger, Marc J. ^{[1
]}

机构：

[1] Tufts Univ, Sch Med, Baystate Med Ctr, Dept Internal Med, Springfield, MA 01199 USA

来源：

EXPERT OPINION ON DRUG SAFETY | 2012年 / 11卷 / 02期

关键词：

bleeding; clinical efficacy; eptifibatide; glycoproteins IIb/IIIa inhibitors; PERCUTANEOUS CORONARY INTERVENTION; ACUTE MYOCARDIAL-INFARCTION; TISSUE-PLASMINOGEN-ACTIVATOR; GLYCOPROTEIN IIB/IIIA BLOCKADE; RANDOMIZED-TRIALS; BLOOD-TRANSFUSION; THROMBOCYTOPENIA; INTEGRIN; THROMBOLYSIS; BIVALIRUDIN;

D O I：

10.1517/14740338.2012.650164

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Introduction: Eptifibatide is a glycoprotein IIb/IIIa inhibitor that blocks the final common pathway of platelet aggregation. Its major adverse effect is bleeding. Balancing its safety and efficacy is paramount for its appropriate usage. Areas covered: The development of eptifibatide and its mechanism of action are explored. Clinical trials evaluating its efficacy and safety in a variety of clinical settings, as well as newer dosing regimens, are discussed. Readers will be able to understand the bleeding risks of eptifibatide in specific patient populations. Expert opinion: The risk of bleeding with eptifibatide needs to be weighed against the potential benefits. Understanding which patients are at higher risk of bleeding will help the clinician make appropriate decisions.

引用

页码：315 / 324

页数：10

共 60 条

[1] 2011 ACCF/AHA Focused Update Incorporated Into the ACC/AHA 2007 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines [J].

Anderson, Jeffrey L. ;

Adams, Cynthia D. ;

Antman, Elliott M. ;

Bridges, Charles R. ;

Califf, Robert M. ;

Casey, Donald E., Jr. ;

Chavey, William E., II ;

Fesmire, Francis M. ;

Hochman, Judith S. ;

Levin, Thomas N. ;

Lincoff, A. Michael ;

Peterson, Eric D. ;

Theroux, Pierre ;

Wenger, Nanette Kass ;

Wright, R. Scott ;

Ettinger, Steven M. ;

Ganiats, Theodore G. ;

Jneid, Hani ;

Philippides, George J. ;

Zidar, James Patrick ;

Jacobs, Alice K. ;

Albert, Nancy ;

Hochman, Judith S. ;

Creager, Mark A. ;

Kushner, Frederick G. ;

Ohman, Erik Magnus ;

Guyton, Robert A. ;

Stevenson, William G. ;

Halperin, Jonathan L. ;

Yancy, Clyde W. .

CIRCULATION, 2011, 123 (18) :E426-E579

[2] EXTRACELLULAR-FREE CA++ ACCOUNTS FOR THE SEX DIFFERENCE IN THE AGGREGATION OF HUMAN PLATELETS IN CITRATED PLATELET-RICH PLASMA [J].

BELL, DN ;

SPAIN, S ;

GOLDSMITH, HL .

THROMBOSIS RESEARCH, 1990, 58 (01) :47-60

[3] EXPOSURE OF PLATELET FIBRINOGEN RECEPTORS BY ADP AND EPINEPHRINE [J].

BENNETT, JS ;

VILAIRE, G .

JOURNAL OF CLINICAL INVESTIGATION, 1979, 64 (05) :1393-1401

[4] Occurrence and clinical significance of thrombocytopenia in a population undergoing high-risk percutaneous coronary revascularization [J].

Berkowitz, SD ;

Sane, DC ;

Sigmon, KN ;

Shavender, JH ;

Harrington, RA ;

Tcheng, JE ;

Topol, EJ ;

Califf, RM .

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 1998, 32 (02) :311-319

[5]

Berkowitz SD, 1997, CIRCULATION, V95, P809

[6] Acute thrombocytopenia after treatment with tirofiban or eptifibatide is associated with antibodies specific for ligand-occupied GPIIb/IIIa [J].

Bougie, DW ;

Wilker, PR ;

Wuitschick, ED ;

Curtis, BR ;

Malik, M ;

Levine, S ;

Lind, RN ;

Pereira, J ;

Aster, RH .

BLOOD, 2002, 100 (06) :2071-2076

[7] Eptifibatide and low-dose tissue plasminogen activator in acute myocardial infarction - The integrilin and low-dose thrombolysis in acute myocardial infarction (INTRO AMI) trial [J].

Brener, SJ ;

Zeymer, U ;

Adgey, AAJ ;

Vrobel, TR ;

Ellis, SG ;

Neuhaus, KL ;

Juran, N ;

Ivanc, TB ;

Ohman, EM ;

Strony, J ;

Kitt, M ;

Topol, EJ .

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2002, 39 (03) :377-386

[8] Suture closure of femoral arterial puncture sites after coronary angioplasty followed by same-day discharge [J].

Carere, RG ;

Webb, JG ;

Buller, CEH ;

Wilson, M ;

Rahman, T ;

Spinelli, J ;

Anis, AH .

AMERICAN HEART JOURNAL, 2000, 139 (01) :52-58

[9] THROMBOLYSIS IN MYOCARDIAL-INFARCTION (TIMI) TRIAL, PHASE-I - A COMPARISON BETWEEN INTRAVENOUS TISSUE PLASMINOGEN-ACTIVATOR AND INTRAVENOUS STREPTOKINASE - CLINICAL FINDINGS THROUGH HOSPITAL DISCHARGE [J].

CHESEBRO, JH ;

KNATTERUD, G ;

ROBERTS, R ;

BORER, J ;

COHEN, LS ;

DALEN, J ;

DODGE, HT ;

FRANCIS, CK ;

HILLIS, D ;

LUDBROOK, P ;

MARKIS, JE ;

MUELLER, H ;

PASSAMANI, ER ;

POWERS, ER ;

RAO, AK ;

ROBERTSON, T ;

ROSS, A ;

RYAN, TJ ;

SOBEL, BE ;

WILLERSON, J ;

WILLIAMS, DO ;

ZARET, BL ;

BRAUNWALD, E .

CIRCULATION, 1987, 76 (01) :142-154

[10] A NEW MURINE MONOCLONAL-ANTIBODY REPORTS AN ACTIVATION-DEPENDENT CHANGE IN THE CONFORMATION AND OR MICROENVIRONMENT OF THE PLATELET GLYCOPROTEIN IIB/IIIA COMPLEX [J].

COLLER, BS .

JOURNAL OF CLINICAL INVESTIGATION, 1985, 76 (01) :101-108

← 1 2 3 4 5 6 →